statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Invivyd provides Pemgarda 2024 net product revenue guidance...

Invivyd provides Pemgarda 2024 net product revenue guidance

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Invivyd gets EUA from FDA for Pemgarda in COVID-19 in adults and adolescents

PEMGARDA now commercially available in the U.S. for pre-exposure prophylaxis (PrEP) of COVID-19 in certain adults and adolescents with moderate-to-severe immune compromise Based on anticipated net...

Invivyd Provides PEMGARDA Launch Update and Announces 2024 Net Product Revenue Guidance in the Range of $150 Million to $200 Million

We can readily understand why investors are attracted to unprofitable companies. For example, Invivyd ( NASDAQ:IVVD...

Is Invivyd (NASDAQ:IVVD) In A Good Position To Invest In Growth?

Morgan Stanley upgraded shares of Invivyd (NASDAQ:IVVD  Free Report) from an equal weight rating to an overweight rating in a research note issued to investors on Tuesday morning, MarketBeat...

Invivyd (NASDAQ:IVVD) Upgraded at Morgan Stanley

Invivyd (IVVD) has disclosed a new risk, in the Regulation category. Invivyd faces a significant business risk with its EUA for PEMGARDA, which hin...

Invivyd's Financial Stability Hangs in the Balance as HHS Reviews PEMGARDA's Emergency Use Authorization

For the last three days, A.I.dvisor has detected that IVVD's AroonDown red line is above 70 while the AroonUp green line is below 30 for three straight days. This move could indicate a strong...

Invivyd (IVVD, $4.44) Aroon Indicator entered a Downtrend on March 28, 2024.

Invivyd sees cash runway into 4Q24

Invivyd reports 2023 EPS ($1.81), consensus ($1.56)

Received emergency use authorization for PEMGARDA , a monoclonal antibody (mAb) authorized in the U.S. for pre-exposure prophylaxis (PrEP) of COVID-19 in certain adults and adolescents with...

Invivyd Reports Full Year 2023 Financial Results and Recent Business Highlights

Invivyd, Inc. engages in the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The firm develops antibodies that can neutralize SARS-CoV-2, SARS-CoV-1, and additional emergent coronaviruses. It offers, ADG20, a monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses. The company was founded by Tillman U. Gerngross, Ren Russo and Laura Walker on June 3, 2020 and is headquartered in Waltham, MA.

Watchers	4,760
52-Wk Low	$0.9802
52-Wk High	$5.20

Volume	414,505.00
52-Wk High	$5.20
52-Wk Low	$0.9802

Period	Estimated	Reported	Surprise	Result
Q2'24	-$0.36	--	--	N/A
Q1'24	-$0.47	-$0.38	18.57%	BEAT
Q4'23	-$0.44	-$0.67	-54.02%	MISSED
Q3'23	-$0.51	-$0.36	28.71%	BEAT
Q2'23	-$0.37	-$0.46	-24.32%	MISSED

IVVD Invivyd Inc

About

Feed

News

Sentiment

Earnings

Fundamentals